10-K: Agenus Inc. 2023 Annual Report: Focus on Immuno-Oncology and Strategic Partnerships

Agenus Inc.'s 2023 annual report highlights its focus on immuno-oncology, strategic partnerships, and the advancement of its lead drug candidates.

Summary

• Agenus is a clinical-stage biotechnology company specializing in developing therapies to activate the body's immune system against cancer and infections.
• The company's pipeline includes immune-modulatory antibodies, adoptive cell therapies, and vaccine adjuvants.
• Agenus's primary focus is immuno-oncology (I-O), with a diverse pipeline supported by in-house capabilities, including cGMP manufacturing and a clinical operations platform.
• The company's most advanced antibody candidates are botensilimab and balstilimab, with botensilimab currently in Phase 2 trials for metastatic colorectal cancer, pancreatic cancer, and melanoma.
• In April 2023, botensilimab in combination with balstilimab received Fast Track designation from the FDA for the treatment of patients with not-microsatellite instability-high metastatic colorectal cancer with no active liver involvement.
• Agenus completed enrollment in a Phase 1 trial (n~150) and randomized Phase 2 trial (n~230) in October 2023, with topline data expected in the second half of 2024.
• In the 70 efficacy evaluable patients in the refractory MSS mCRC NLM treatment setting, a 24% RECIST v1.1 response rate was observed in those treated with the BOT/BAL combination.
• The 12-month overall survival rate is 74% with median OS not yet reached.
• Agenus is pursuing a global regulatory strategy and aims to initiate submission of a BLA to the FDA for a potential accelerated approval by the end of 2024, followed by a planned submission to the EMA in the first half of 2025.
• Agenus has established strategic partnerships with companies like BMS, Gilead, Incyte, and Betta to advance innovation and finance the business.
• The company's subsidiary, SaponiQx, is focused on saponin-based adjuvant discovery and manufacturing, with its proprietary adjuvant, STIMULON QS-21, forming an integral part of the AS01 adjuvant used in several leading vaccines.
• Agenus had $76.1 million of cash, cash equivalents and short-term investments as of December 31, 2023.
• The company believes that its cash resources, plus potential milestone payments, out-licensing opportunities, and the sale of non-strategic assets, will be sufficient to satisfy its liquidity requirements through the end of the year and into 2025.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the company's clinical progress and strategic partnerships, but also acknowledges the financial risks and challenges inherent in the biotechnology industry. The positive clinical data and strategic focus are encouraging, but the need for additional capital and the competitive landscape temper the overall sentiment.

Positives

• Agenus has a diverse pipeline of immuno-oncology therapeutics, including antibodies, cell therapies, and vaccine adjuvants.
• The company has fully integrated end-to-end capabilities, from novel target discovery to cGMP manufacturing.
• Agenus has established strategic partnerships with industry leaders to advance innovation and finance the business.
• The company's lead program, botensilimab/balstilimab, has shown promising clinical results in metastatic colorectal cancer.
• Agenus is pursuing a global regulatory strategy with plans to submit a BLA to the FDA by the end of 2024.
• SaponiQx is developing a sustainable and cost-efficient alternative to conventionally extracted QS-21, which is used in high-performance vaccines.

Negatives

• Agenus has incurred net losses in every year since its inception and anticipates that it will continue to incur net losses in the future.
• The company will require additional capital to fund its operations and may not be able to obtain necessary financing.
• The regulatory approval process for the company's product candidates is uncertain and will be lengthy.
• The company's product candidates may cause undesirable side effects.
• The company faces intense competition in the pharmaceutical and biotechnology industries.
• The company is dependent on third parties for the manufacture of clinical supplies of certain of its product candidates.

Risks

• The company's business is highly dependent on the success of botensilimab and related combination therapy programs.
• Preliminary or interim data from clinical trials could change materially by the time the data is finalized.
• The company may encounter difficulties in enrolling patients in clinical trials.
• The company may not be able to commercialize its product candidates.
• The company's product candidates may cause undesirable side effects.
• The company's competitors may have superior products, manufacturing capability, expertise and/or resources.
• The company is dependent upon third parties to further develop and commercialize certain of its antibody programs.
• The regulatory approval process for the company's product candidates is uncertain and will be lengthy.
• The company may be unable to obtain and enforce patent protection for its product candidates and related technology.
• The company may encounter difficulties in managing its recent growth.
• The company's stock may be delisted from The Nasdaq Capital Market.

Future Outlook

Agenus aims to initiate submission of a BLA to the FDA for a potential accelerated approval of botensilimab/balstilimab by the end of 2024, followed by a planned submission to the EMA in the first half of 2025. The company plans to expand combinations with botensilimab by integrating balstilimab and other complementary approaches within its clinical portfolio.

Management Comments

• Agenus envisions a future where I-O combinations will unlock the full potential of cancer treatment and provide patients with significantly extended and improved lives.
• We believe our fully integrated, end-to-end capabilities for novel target discovery, antibody generation, and cell line development to our cGMP manufacturing and clinical development and operations capabilities, together with a comprehensive and complementary portfolio will uniquely position us to produce potential novel therapies on accelerated timelines.
• Our strategy revolves around pioneering optimal combination treatments for cancer patients, with botensilimab as our cornerstone.

Industry Context

The I-O drug landscape is crowded with several competitors developing assets against a number of targets. Agenus and its partners have I-O antibody programs in clinical stage development targeting various pathways, including PD-1, CTLA-4, TIM-3, LAG-3, CD73, TGF b, CD137, ILT2, and TIGIT. Many companies have antibody-based products on the market or in clinical development that are directed to the same biological targets as these programs.

Comparison to Industry Standards

• Agenus's 24% response rate in refractory MSS mCRC NLM patients treated with botensilimab/balstilimab is significantly higher than the 1% to 6.1% response rate observed with standard of care therapies in a similar population.
• Agenus's manufacturing process for certain of its product candidates has not been scaled up to commercial production, which is a common challenge for biotechnology companies.
• Agenus's ability to deliver clinical grade material from research cell banks in approximately six to nine months is significantly faster than the industry average of 12-18 months.
• The durability offered by QS-21 STIMULON has been validated by Shingrix, with protection exceeding nine years, but the supply is limited due to reliance on a complicated and expensive extraction process from a Chilean soap bark tree.

Related Party Transactions

• During the years ended December 31, 2023, 2022 and 2021, our Audit and Finance Committee approved the performance of research and development manufacturing services totaling $150,000, $106,000 and $291,000, respectively, for Protagenic Therapeutics, Inc.
• In 2023, our Audit and Finance Committee approved a contract between Avillion Life Sciences LTD and Agenus for the performance of up to $450,000 of clinical consulting services.
• Zachary Armen, the Head of Investor Relations of Agenus, is the son of Dr. Garo Armen our principal executive officer.

Stakeholder Impact

• The company's focus on immuno-oncology and the development of new cancer therapies has the potential to benefit patients by providing new treatment options.
• The company's strategic partnerships and collaborations may lead to increased innovation and faster development of new therapies.
• The company's financial performance and ability to raise capital will impact its ability to continue its research and development efforts.
• The company's stock price may be affected by the success of its clinical trials, regulatory approvals, and commercialization efforts.

Next Steps

• Agenus aims to initiate submission of a BLA to the FDA for a potential accelerated approval of botensilimab/balstilimab by the end of 2024.
• Agenus plans a planned submission to the EMA in the first half of 2025.
• Agenus plans to expand combinations with botensilimab by integrating balstilimab and other complementary approaches within its clinical portfolio.

Key Dates

Keywords

immuno-oncology, botensilimab, balstilimab, cancer therapy, clinical trials, antibody, vaccine adjuvant, cGMP manufacturing, strategic partnerships, FDA approval, metastatic colorectal cancer, MiNK Therapeutics, SaponiQx, QS-21 STIMULON